SCHEMBL2879895

SCHEMBL2879895

Cc1ccc(-c2ccccc2-c2nc(-c3ccccc3-c3ccc(C)cc3)nc(-c3ccccc3-c3ccc(C)cc3)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 9/20 0.46
RAB9A P51151 9/20 0.46
L3MBTL1 Q9Y468 5/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
NFKB1 P19838 4/20 0.46
NFKB2 Q00653 4/20 0.46
RELA Q04206 4/20 0.46
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
TP53 P04637 4/20 0.46
MAPK1 P28482 2/20 0.46
TDP1 Q9NUW8 2/20 0.45
PKM P14618 3/20 0.45
MAPT P10636 2/20 0.45
POLB P06746 2/20 0.45
LMNA P02545 1/20 0.45
ALDH1A1 P00352 2/20 0.44
NR1H2 P55055 1/20 0.43
NR1H3 Q13133 1/20 0.43
HPGD P15428 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8036362 0.85 LMNA (0.50) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL20344232 0.81 CYP1A2 (0.47) NPC1RAB9AL3MBTL1SMN1; SMN2NFKB1
SCHEMBL12636524 0.81 NPC1 (0.43) NPC1RAB9AL3MBTL1SMN1; SMN2NFKB1
SCHEMBL29688196 0.80 LMNA (0.53) NPC1RAB9AL3MBTL1SMN1; SMN2NFKB1
SCHEMBL3294988 0.80 LMNA (0.53) NPC1RAB9AL3MBTL1SMN1; SMN2NFKB1
SCHEMBL336961 0.80 GPR55 (0.54) NPC1RAB9AL3MBTL1SMN1; SMN2MEN1
SCHEMBL25774971 0.80 L3MBTL1 (0.68) NPC1RAB9AL3MBTL1SMN1; SMN2MAPK1
SCHEMBL29940261 0.79 L3MBTL1 (0.38) NPC1RAB9AL3MBTL1SMN1; SMN2NFKB1
SCHEMBL6014197 0.79 ACHE (0.62) NPC1RAB9AL3MBTL1SMN1; SMN2MEN1
Water SCHEMBL312989 0.78 HPGD (0.50) NPC1RAB9AL3MBTL1SMN1; SMN2NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6821643-B1 SATISFACTORY EMISSION IN THE VISIBLE SPECTRUM FROM BLUE TO LONGER WAVELENGTH REGIONS XEROX CORPORATION 2004-11-23 US claimed
US-6225467-B1 UNIFORM LUMINESCENCE, ELECTROLUMINESCENT EFFICIENCY, DURABILITY, LOW DRIVING VOLTAGE; FOR USE IN FLAT-PANEL EMISSIVE DISPLAY TECHNOLOGIES, INCLUDING TELEVISION SCREENS, COMPUTER SCREENS XEROX CORPORATION 2001-05-01 US claimed
US-7777407-B2 Organic light emitting devices comprising a doped triazine electron transport layer LG DISPLAY CO., LTD. (KR) 2010-08-17 US disclosed
US-20090102373-A1 Electroluminescent device HAYOZ PASCAL 2009-04-23 US disclosed
US-20080199726-A1 Electroluminescent Device CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2008-08-21 US disclosed
EP-1743011-A1 ELECTROLUMINESCENT DEVICE CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement (CH) 2007-01-17 EP disclosed
US-20060251920-A1 Organic light emitting devices comprising a doped triazine electron transport layer XEROX CORPORATION 2006-11-09 US disclosed
US-20060251919-A1 Organic light emitting devices XEROX CORPORATION 2006-11-09 US disclosed
US-20060135766-A1 Electroluminescent device CIBA SPECIALTY CHEMICALS CORP. 2006-06-22 US disclosed
EP-1597938-A2 ELECTROLUMINESCENT DEVICE Ciba SC Holding AG (CH) 2005-11-23 EP disclosed
WO-2005105950-A1 ELECTROLUMINESCENT DEVICE CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2005-11-10 WO disclosed
US-6821643-B1 SATISFACTORY EMISSION IN THE VISIBLE SPECTRUM FROM BLUE TO LONGER WAVELENGTH REGIONS XEROX CORPORATION 2004-11-23 US disclosed
WO-2004077885-A2 ELECTROLUMINESCENT DEVICE CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2004-09-10 WO disclosed
US-6225467-B1 UNIFORM LUMINESCENCE, ELECTROLUMINESCENT EFFICIENCY, DURABILITY, LOW DRIVING VOLTAGE; FOR USE IN FLAT-PANEL EMISSIVE DISPLAY TECHNOLOGIES, INCLUDING TELEVISION SCREENS, COMPUTER SCREENS XEROX CORPORATION 2001-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135766-A1 Electroluminescent device TAAR5, TYR, TRPC5 NPC1 4847/4885RAB9A 3537/4885L3MBTL1 1776/4885
US-20090102373-A1 Electroluminescent device TAAR5, TYR, TRPC5 NPC1 4847/4885RAB9A 3537/4885L3MBTL1 1776/4885
US-20080199726-A1 Electroluminescent Device TPMT, THPO, KYNU NPC1 4744/4885RAB9A 4428/4885L3MBTL1 1449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.